Loading clinical trials...
Loading clinical trials...
A Phase I Clinical Study to Evaluate the Safety, Efficacy, and PK/PD Characteristics of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
Conditions
Interventions
HSK47977
Locations
1
China
Chinese Academy of Medical Sciences Blood Diseases Hospital
Tianjin, China
Start Date
August 28, 2025
Primary Completion Date
December 1, 2027
Completion Date
December 1, 2027
Last Updated
December 19, 2025
NCT05442515
NCT06230224
NCT06528301
NCT05098613
NCT06731699
NCT06678282
Lead Sponsor
Haisco Pharmaceutical Group Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions